Who are HMG CoA inhibitor's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Crestor, Lipitor, FLUVASTATIN SODIUM, Lescol, statin + ezetimibe, pioglitazone + simvastatin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hmg-coa-inhibitor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

HMG CoA inhibitor — Competitive Intelligence Brief

HMG CoA inhibitor (HMG CoA inhibitor) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Statin (HMG-CoA reductase inhibitor). Area: Cardiovascular.

marketed Statin (HMG-CoA reductase inhibitor) HMG-CoA reductase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

HMG CoA inhibitor (HMG CoA inhibitor) — AstraZeneca. HMG-CoA inhibitors block the enzyme HMG-CoA reductase, which catalyzes an early and rate-limiting step in cholesterol synthesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
HMG CoA inhibitor TARGET	HMG CoA inhibitor	AstraZeneca	marketed	Statin (HMG-CoA reductase inhibitor)	HMG-CoA reductase
Crestor	rosuvastatin	AstraZeneca	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	2003-01-01
Lipitor	atorvastatin	Pfizer Inc.	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	1996-12-17
FLUVASTATIN SODIUM	FLUVASTATIN SODIUM		marketed		HMG-CoA reductase	1993-01-01
Lescol	FLUVASTATIN	Novartis	marketed	HMG-CoA Reductase Inhibitor	HMG-CoA reductase	1993-01-01
statin + ezetimibe	statin + ezetimibe	University of Roma La Sapienza	marketed	Lipid-lowering agent combination (statin + cholesterol absorption inhibitor)	HMG-CoA reductase; NPC1L1 transporter
pioglitazone + simvastatin	pioglitazone + simvastatin	University of Leipzig	marketed	Thiazolidinedione + HMG-CoA reductase inhibitor combination	PPAR-γ (pioglitazone); HMG-CoA reductase (simvastatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2037-06-07 — Lipitor · 11654106 · US
2037-06-07 — Lipitor · 11369567 · US

Sponsor landscape (Statin (HMG-CoA reductase inhibitor) class)

Organon and Co · 2 drugs in this class
AstraZeneca · 1 drug in this class
Mitsukoshi Health and Welfare Foundation · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class
Shenyang Northern Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HMG CoA inhibitor — Competitive Intelligence Brief. https://druglandscape.com/ci/hmg-coa-inhibitor. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab